DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a San Diego-based precision dermatology company focused on non-invasive genomic diagnostics for skin cancer, primarily through its Pigmented Lesion Assay for melanoma detection. The company filed an S-1 registration statement with the SEC in May 2017 in an early push toward the public markets within the healthcare diagnostics sector. DermTech ultimately completed its public debut in August 2019 through a business combination with Constellation Alpha Capital Corp (Nasdaq: CNAC), a blank-check company sponsored by Constellation Alpha Capital LLC that had completed its IPO in 2016. Following the merger, the combined company traded under the DMTK ticker on Nasdaq. Visit SpacDesk and sign up for full access to detailed filing data, sponsor profiles, and transaction timelines on DermTech and hundreds of other SPAC deals.